CoChat

EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update

Open access
Landewé, Robert B M, Kroon, Féline P B, Alunno, Alessia, Najm, Aurélie, Bijlsma, Johannes WJ, Burmester, Gerd-Rüdiger R, Caporali, Roberto, Combe, Bernard, Conway, Richard, Curtis, Jeffrey R, Elkayam, Ori, Gossec, Laure, Heijstek, Marloes W, Haupt, Lukas, Iagnocco, Annamaria, Isaacs, John D, Juhász, István Ábel, Makri, Suzi, Mariette, Xavier, McInnes, Iain B, Mehta, Puja, Mueller-Ladner, Ulf, Schulze-Koops, Hendrik, Smolen, Josef S, Wiek, Dieter, Winthrop, Kevin L, Navarro-Compán, Victoria, Machado, Pedro M · 2022 · Annals of the Rheumatic Diseases
Cited by 165

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

The first EULAR provisional recommendations on the management of rheumatic and musculoskeletal diseases (RMDs) in the context of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), largely based on expert opinion, were published in June 2020. Since then, an unprecedented number of clinical studies have accrued in the literature. Several SARS-CoV-2 vaccines have been approved for population-wide vaccination programmes in EULAR-affiliated countries. Studies regarding vaccination of patients with (inflammatory) RMDs have released their first results or are underway. EULAR found it opportune to carefully review to what extent the initially consensus expert recommendations stood the test of time, by challenging them with the recently accumulated body of scientific evidence, and by incorporating evidence-based advice on SARS-CoV-2 vaccination. EULAR started a formal (first) update in January 2021, performed a systematic literature review according to EULAR’s standard operating procedures and completed a set of updated overarching principles and recommendations in July 2021. Two points to consider were added in November 2021, because of recent developments pertaining to additional vaccination doses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2021-222006

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Metadata

Authors
Landewé, R. B. M., Kroon, F. P. B., Alunno, A., Najm, A., Bijlsma, J. W., Burmester, G.-R. R., Caporali, R., Combe, B., Conway, R., Curtis, J. R., Elkayam, O., Gossec, L., Heijstek, M. W., Haupt, L., Iagnocco, A., Isaacs, J. D., Juhász, I. Á., Makri, S., Mariette, X., McInnes, I. B., Mehta, P., Mueller-Ladner, U., Schulze-Koops, H., Smolen, J. S., Wiek, D., Winthrop, K. L., Navarro-Compán, V., & Machado, P. M.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2022-12
Volume
81
Issue
12
Pages
1628-1639
ISSN
0003-4967 (ISSN-L)
OpenAlex
W4213451248
Cited by
165
References
5
FWCI
18.03
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. https://app.cochat.ai/papers/10.1136/annrheumdis-2021-222006
The paper
Landewé, R. B. M., Kroon, F. P. B., Alunno, A., Najm, A., Bijlsma, J. W., Burmester, G.-R. R., Caporali, R., Combe, B., Conway, R., Curtis, J. R., Elkayam, O., Gossec, L., Heijstek, M. W., Haupt, L., Iagnocco, A., Isaacs, J. D., Juhász, I. Á., Makri, S., Mariette, X., . . . Machado, P. M. (2022). EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2021-222006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.